back

Bladder Cancer Clinical Trials in Georgia

Cancer Type = Bladder Cancer

Cancer Type = Bladder Cancer

NCI ID Cancer Type Trial Name
There are currently 16 active Bladder Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03288545
Protocol IDs
SGN22E-002
NCI-2017-01927
2.
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03397394
Protocol IDs
CO-338-085
NCI-2018-01112
3.
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
Cancer Type
Bladder Cancer, Kidney Cancer
NCI ID
NCT02872714
Protocol IDs
INCB 54828-201
NCI-2016-01513
4.
A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination With Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients With Low PD-L1 Expression
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03785925
Protocol IDs
18-214-10
NCI-2019-01752
CA045-012
5.
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab / BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT03519256
Protocol IDs
CA209-9UT
NCI-2018-01177
2017-003581-27
6.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
7.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Bladder Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
8.
A Phase II Study of Nivolumab Combined with Ipilimumab for Patients with Advanced Rare Genitourinary Tumors
Cancer Type
Adrenal Cancer, Bladder Cancer, Germ Cell Tumor, Penile Cancer, Prostate Cancer
NCI ID
NCT03333616
Protocol IDs
17-423
NCI-2018-00182
9.
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT02108652
Protocol IDs
GO29293
10.
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT03091660
Protocol IDs
S1602
S1602
NCI-2016-00451
S1602
11.
A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT02516241
Protocol IDs
D419BC00001
NCI-2015-02054
12.
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma
Cancer Type
Bladder Cancer, Kidney Cancer
NCI ID
NCT02567409
Protocol IDs
9947
NCI-2015-01642
PHII-135
13.
An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.
Cancer Type
Bladder Cancer, Breast Cancer
NCI ID
NCT01953926
Protocol IDs
PUMA-NER-5201
NCI-2014-00495
2013-002872-42
14.
Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy
Cancer Type
Bladder Cancer
NCI ID
NCT01489813
Protocol IDs
EU2010-11
NCI-2014-02088
IRB00050273
15.
Phase II Study of Adjuvant Conformal Radiotherapy in High Risk Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT01954173
Protocol IDs
RAD2271-12
NCI-2013-01381
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
NCORP Trial
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Cancer Type
Bladder Cancer
NCI ID
NCT03244384
Protocol IDs
A031501
A031501
NCI-2017-01425
A031501
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Us

Resources & Education

Media, News & Events

More Helpful Links

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.